Pharmaceutical

STAT+: Flagship Pioneering startup lays off a third of ...

Sonata Therapeutics, a startup created two years ago through the merger of two F...

STAT+: Medicare Advantage enrollment races past 33 million

Roughly 33.4 million people were enrolled in a Medicare Advantage plan as the ca...

STAT+: Bipartisan group of lawmakers warns of a rising ...

Lawmakers called for strengthening U.S. life sciences companies and safeguarding...

More people die after smoking drugs than injecting them...

Smoking has surpassed injecting as the most common way of taking drugs in U.S. o...

STAT+: Louisiana, Oregon deals show health insurer acqu...

On Tuesday, two different proposed insurance plan acquisitions on different side...

STAT+: Pharmalittle: We’re reading about kids taking We...

A small but rapidly growing number of U.S. adolescents began treatment with Novo...

Alnylam thickened the plot

The results of Alnylam Pharmaceuticals’ Phase 3 cardiovascular study was already...

Opinion: I’ve reported on the health of every president...

The leading chronicler of presidents and health ponders the question: How old is...

Q&A: Solving astronauts’ health challenges in deep spac...

Dorit Donoviel and her team at the Translational Research Institute for Space He...

STAT+: For unlucky mountaineers, tundra explorers, and ...

The FDA's approval of Aurlumyn (ilosprost) culminates decades of research that h...

Dragonfly and Gilead enter partnership for cancer therapy

Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences...

FDA grants orphan drug status to Ionis’ olezarsen for F...

The US FDA has granted orphan drug designation to Ionis Pharmaceuticals’ olezars...

Xyphos and Kelonia link for immuno-oncology drug develo...

Xyphos Biosciences has entered an agreement with Kelonia Therapeutics to develop...

GSK concludes Aiolos Bio acquisition for $1.4bn

GSK has successfully concluded the acquisition of Aiolos Bio in a deal that coul...

Psychedelic treatments for mental health: Is there subs...

The success of recent trials treating mental health problems with psychedelic th...

MYK-224 by Bristol-Myers Squibb for Diastolic Heart Fai...

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in P...